menu
    • menu

    Company profile for Cipla

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Since inception in 1935, caring has been at the core of everything we do at Cipla. For patients, caring is a promise that we...
    Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Since inception in 1935, caring has been at the core of everything we do at Cipla. For patients, caring is a promise that we will do whatever it takes to ensure they have continued access to the highest quality medicines at affordable prices; whether a disease affects millions or just a few hundreds.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ciplaindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumba...
    Telephone
    Telephone
    +91 22 23082891 / 23095521
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cipla.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Japan

    Not Confirmed

    envelop Contact Supplier

    CPhI Japan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 783

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Artificial intelligence (AI) is emerging as a transformative force in drug discovery and development. The global AI in drug discovery market was valued at US$ 1.99 billion in 2024 and is estimated to reach US$ 2.65 billion in 2025. Going forward, the market is expected to grow at an impressive compounded annual growth rate (CAGR) of 29.6 percent, to reach a market size of US$ 35.42 billion by 2034, says a report by Polaris Market Research. This growth expectation mirrors the eagerness within the biopharma industry to leverage AI in order to overcome the traditional barriers of lengthy timelines, exorbitant costs, and high failure rates. This eagerness is also being manifested in deal making — Big Pharma has been busy forging alliances with AI-driven drug discovery companies. Over the last two years, almost every big drugmaker, including Novo Nordisk, Merck, BMS, Pfizer, AstraZeneca, Otsuka Pharmaceutical, Novartis and Sanofi, has signed deals with various AI drug discovery companies. PharmaCompass' compilation shows there are scores of molecules discovered by AI currently in discovery and developmental phases, demonstrating the technology's growing impact on pharmaceutical pipelines.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available) Novo, Lilly, BMS invest in AI partnerships; Recursion, Exscientia merge to create AI powerhouse With the transformative potential of AI becoming increasingly evident, we witnessed a slew of deals in the biopharma industry over the last six months. A significant deal in the AI drug discovery space was the merger of two leaders — Recursion and Exscientia — that took place in November last year. Exscientia is now a wholly-owned subsidiary of Recursion. The merger has created a global technology-enabled drug discovery leader with end-to-end capabilities. The merged entity has over 10 clinical and preclinical programs, and around 10 advanced discovery programs in the pipeline.  Apart from this merger, several large drugmakers have struck deals with AI drug discovery firms since September last year. For instance, in January this year, Valo Health and Novo Nordisk expanded their collaboration to discover and develop novel treatments for cardiometabolic diseases. This deal, valued at up to US$ 4.8 billion, aims to harness the power of AI and extensive human datasets. Building on their initial 2023 partnership, it will enable the development of up to 20 drug programs.  Similarly, Pfizer, which is already big on AI, extended its AI drug discovery pact with PostEra and also partnered IgnitionAI to enhance drug discovery — all within the last six months. And Novartis struck a drug discovery deal with Generate BioMedicines in September. Insilico Medicine has been actively forging partnerships. In January, Insilico entered a second exclusive global license agreement with Menarini Group for an AI-discovered preclinical asset targeting high unmet needs in oncology. Insilico also has a tie-up with Sanofi, dating back to 2022. In December 2024, AI Proteins announced a research collaboration and option agreement with BMS to design and optimize mini-proteins for therapeutic use. And in September, Eli Lilly joined hands with Genetic Leap to accelerate the development of genetic medicines. Lilly will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against selected targets.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  AI leads to faster target identification; Insilico, BenevolentAI’s candidates in trials Computational biology, and especially AI, has fundamentally changed the drug discovery paradigm. The traditional method of drug discovery used to take 13 to 15 years, costing an average of US$ 2.5 billion in investment before a drug got approved and launched in the market. Additionally, less than 10 percent of candidates in phase 1 clinical trials used to end up getting approved by the US Food and Drug Administration (FDA). All that has begun to change. According to Khair ElZarrad, Director of the Office of Medical Policy within FDA’s Center for Drug Evaluation and Research, since 2016, FDA has received approximately 300 submissions that reference AI use as of May 2024. These submissions range from drug development, drug discovery, clinical research, clinical trials as well as post-market safety surveillance and manufacturing. Though we are yet to witness an AI-generated candidate translate into an approved therapy, target identification in drug discovery is visibly becoming a lot faster. This is the process that identifies specific molecules or pathways in the human body that are linked to a disease. The best example of dramatic acceleration of timelines is Insilico Medicine’s development of INS018_055, a candidate for idiopathic pulmonary fibrosis that entered phase 2 trials in June 2023. Using their AI platform PandaOmics, researchers at Insilico compressed target identification from years to just 18 months. Similarly, BenevolentAI successfully employed their AI platform to identify a new target for ulcerative colitis, leading to the development of BEN-8744, a candidate that has been in phase 1a clinical trials since August 2023.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Oncology leads AI drug discovery market; Recursion shows how to repurpose drugs using AI The integration of AI in oncology research has been impactful, accounting for the largest revenue share (about 22.4 percent) in the AI drug discovery market in 2023. AI technologies have accelerated the discovery and development of new cancer treatments, bolstered personalized medicine approaches, and improved clinical trial designs in the arena of this complex disease.  Another promising application is drug repurposing, where AI can identify new therapeutic applications for existing drugs. Recursion Pharmaceuticals’ REC-2282 exemplifies this approach. This therapy is currently in phase 2/3 studies for neurofibromatosis type 2 (a genetic condition that causes tumors to grow along nerves). By repurposing compounds already vetted for safety, this strategy can bypass early-stage failures, reducing both time and cost compared to developing entirely new molecules. However, the use of AI in drug discovery is not without challenges. Exscientia’s EXS-21546, designed to treat solid tumors, entered phase 1/2 trials in 2020 but was discontinued in 2023 after modeling suggested that achieving a suitable therapeutic index would be difficult. Though this is a clinical failure, it highlights AI’s value in identifying potential failures earlier on in the development process, saving resources that would have otherwise been spent on later-stage trials.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Our view The Covid-19 pandemic was a time when humanity felt the urgent need to speed up the process of drug discovery, testing and approvals. It also hastened the process of integrating AI into pharmaceutical research, leading to the launch of Covid vaccines in record time. Today, there is no looking back — AI is bringing about a paradigm shift in how drugs are discovered. With increasing reliance on AI, there is hope that drug discovery will be more accurate, efficient and less time and cost consuming.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1292

    https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals

    #PharmaFlow by PHARMACOMPASS
    13 Mar 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Cipla CEO: Tariffs Should Not Dictate Indian Pharma Business
    Cipla CEO: Tariffs Should Not Dictate Indian Pharma Business

    03 Mar 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/tariffs-should-not-dictate-how-indian-drugmakers-do-business-cipla-ceo-says/articleshow/118633708.cms

    ECONOMICTIMES
    03 Mar 2025
    Share Share
    Cipla Beats Q3 Profit View as India Offsets Weak U.S. Sales
    Cipla Beats Q3 Profit View as India Offsets Weak U.S. Sales

    28 Jan 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/indias-cipla-beats-q3-profit-view-strong-demand-north-america-2025-01-28/

    REUTERS
    28 Jan 2025
    Share Share
    Cipla Goa facility receives form 483 with 1 observation
    Cipla Goa facility receives form 483 with 1 observation

    21 Jan 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/markets/stocks/news/cipla-shares-in-focus-after-goa-facility-receives-form-483-with-one-observation-from-usfda/articleshow/117413516.cms?from=mdr

    ECONOMICTIMES
    21 Jan 2025
    Share Share
    Briefs: Cipla and IOL Chemicals and Pharmaceuticals
    Briefs: Cipla and IOL Chemicals and Pharmaceuticals

    21 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/briefs-cipla-and-iol-chemicals-and-pharmaceuticals-16690

    INDPHARMAPOST
    21 Jan 2025
    Share Share
    Cipla rolls out mobile application for asthma screening
    Cipla rolls out mobile application for asthma screening

    06 Jan 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-rolls-out-mobile-application-for-asthma-screening/articleshow/116985856.cms

    ECONOMICTIMES
    06 Jan 2025
    Share Share
    Cipla`s Generics Phytonadione Receives Approval in US
    Cipla`s Generics Phytonadione Receives Approval in US

    03 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214966

    FDA
    03 Jan 2025
    Share Share

    USDMF

    read-more
    read-more

    01

    16a-bromoepiandrosterone

    India
    ASPEN
    Not Confirmed
    arrow

    02

    Abacavir Sulfate Usp

    India
    ASPEN
    Not Confirmed
    arrow

    03

    Abiraterone Acetate

    India
    ASPEN
    Not Confirmed
    arrow

    04

    Abiraterone Acetate Usp

    India
    ASPEN
    Not Confirmed
    arrow

    05

    Acalabrutinib

    India
    ASPEN
    Not Confirmed
    arrow

    06

    Acalabrutinib Maleate

    India
    ASPEN
    Not Confirmed
    arrow

    07

    Acyclovir

    India
    ASPEN
    Not Confirmed
    arrow

    08

    Adefovir Dipivoxil

    India
    ASPEN
    Not Confirmed
    arrow

    09

    Albendazole (b) Usp

    India
    ASPEN
    Not Confirmed
    arrow

    10

    Albendazole Usp

    India
    ASPEN
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla and Formosa Sign Multi-Regional Licensing Deal for Clobetasol Suspension

    Details:

    Cipla has rights to market the innovative treatment, APP13007, a novel, patent protected and USFDA approved ophthalmic product, for post-operative inflammation and pain following ocular surgery.


    Lead Product(s): Clobetasol Propionate

    Therapeutic Area: Neurology Brand Name: APP13007

    Study Phase: Approved FDFProduct Type: Steroid

    Recipient: Formosa Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement March 18, 2025

    blank

    01

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clobetasol Propionate

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Formosa Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Cipla and Formosa Sign Multi-Regional Licensing Deal for Clobetasol Suspension

    Details : Cipla has rights to market the innovative treatment, APP13007, a novel, patent protected and USFDA approved ophthalmic product, for post-operative inflammation and pain following ocular surgery.

    Product Name : APP13007

    Product Type : Steroid

    Upfront Cash : Undisclosed

    March 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla Gets CDSCO Nod to Launch Inhalation Insulin

    Details:

    Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, indicated for the treatment of diabetes.


    Lead Product(s): Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: ApprovedProduct Type: Peptide

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 11, 2024

    blank

    02

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cipla Gets CDSCO Nod to Launch Inhalation Insulin

    Details : Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, indicated for the treatment of diabetes.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Not Applicable

    December 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

    Details:

    Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.


    Lead Product(s): Cefepime,Enmetazobactam

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Orchid Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 29, 2024

    blank

    03

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cefepime,Enmetazobactam

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Orchid Pharma

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

    Details : Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.

    Product Name : Exblifep

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla Signs Agreement With Takeda To Commercialize Vonoprazan in India

    Details:

    Under the terms of this agreement, Takeda has granted Cipla non-exclusive patent licensing rights for the commercialization of Voltapraz (vonoprazan) in India.


    Lead Product(s): Vonoprazan Fumarate

    Therapeutic Area: Gastroenterology Brand Name: Voltapraz

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Takeda Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement June 20, 2024

    blank

    04

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vonoprazan Fumarate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Recipient : Takeda Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Cipla Signs Agreement With Takeda To Commercialize Vonoprazan in India

    Details : Under the terms of this agreement, Takeda has granted Cipla non-exclusive patent licensing rights for the commercialization of Voltapraz (vonoprazan) in India.

    Product Name : Voltapraz

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 20, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla Gets Approval for Generic Somatuline® Depot Injection (Lanreotide)

    Details:

    Lanreotide generic injection is approved by FDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.


    Lead Product(s): Lanreotide Acetate

    Therapeutic Area: Endocrinology Brand Name: Somatuline Depot-Generic

    Study Phase: ApprovedProduct Type: Peptide

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 22, 2024

    blank

    05

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lanreotide Acetate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cipla Gets Approval for Generic Somatuline® Depot Injection (Lanreotide)

    Details : Lanreotide generic injection is approved by FDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.

    Product Name : Somatuline Depot-Generic

    Product Type : Peptide

    Upfront Cash : Not Applicable

    May 22, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sanofi and Cipla Form Exclusive Distribution Partnership for CNS Portfolio in India

    Details:

    Cipla will distribute and promote Sanofi India's CNS product range, including Frisium (clobazam), an anti-epileptic medication, in India.


    Lead Product(s): Clobazam

    Therapeutic Area: Neurology Brand Name: Frisium

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Sanofi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership March 27, 2024

    blank

    06

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clobazam

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Sanofi and Cipla Form Exclusive Distribution Partnership for CNS Portfolio in India

    Details : Cipla will distribute and promote Sanofi India's CNS product range, including Frisium (clobazam), an anti-epileptic medication, in India.

    Product Name : Frisium

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    March 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla Partners with CSIR-CDRI to Develop Formulation for Fungal Keratitis

    Details:

    The partnership allows Cipla to scale up amphotericin, conducting studies and seeking regulatory approvals for commercialization in treating fungal keratitis.


    Lead Product(s): Amphotericin B

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Small molecule

    Recipient: Central Drug Research Institute

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership February 15, 2024

    blank

    07

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amphotericin B

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Recipient : Central Drug Research Institute

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Cipla Partners with CSIR-CDRI to Develop Formulation for Fungal Keratitis

    Details : The partnership allows Cipla to scale up amphotericin, conducting studies and seeking regulatory approvals for commercialization in treating fungal keratitis.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    February 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pulmatrix Stops PUR1900 Phase 2B Enrollment To Preserve Cash

    Details:

    Under the amendment, Cipla and Pulmatrix agreed to halt patient enrollment in the Ph2b study of PUR1900 (itraconazole) at 8 subjects, with Cipla assuming sole responsibility for its development.


    Lead Product(s): Itraconazole

    Therapeutic Area: Infections and Infectious Diseases Brand Name: PUR1900

    Study Phase: Phase IIProduct Type: Small molecule

    Recipient: Pulmatrix

    Deal Size: Undisclosed Upfront Cash: $22.0 million

    Deal Type: Agreement January 08, 2024

    blank

    08

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Itraconazole

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Recipient : Pulmatrix

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Pulmatrix Stops PUR1900 Phase 2B Enrollment To Preserve Cash

    Details : Under the amendment, Cipla and Pulmatrix agreed to halt patient enrollment in the Ph2b study of PUR1900 (itraconazole) at 8 subjects, with Cipla assuming sole responsibility for its development.

    Product Name : PUR1900

    Product Type : Small molecule

    Upfront Cash : $22.0 million

    January 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla to Acquire South Africa-based Actor Pharma

    Details:

    Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.


    Lead Product(s): Glycine,Calcium

    Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Nozohaem

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Actor Pharma

    Deal Size: $48.6 million Upfront Cash: $48.6 million

    Deal Type: Acquisition September 05, 2023

    blank

    09

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glycine,Calcium

    Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

    Highest Development Status : Approved

    Recipient : Actor Pharma

    Deal Size : $48.6 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Cipla to Acquire South Africa-based Actor Pharma

    Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.

    Product Name : Nozohaem

    Product Type : Small molecule

    Upfront Cash : $48.6 million

    September 05, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range

    Details:

    Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.


    Lead Product(s): Vildagliptin

    Therapeutic Area: Endocrinology Brand Name: Galvus

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Novartis Pharmaceuticals Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 11, 2023

    blank

    10

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed

    Cipla

    India
    arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vildagliptin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Recipient : Novartis Pharmaceuticals Corporation

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range

    Details : Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.

    Product Name : Galvus

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    April 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Cipla and get a quotation

    Cipla is a supplier offers 305 products (APIs, Excipients or Intermediates).

    Find a price of Amlodipine Besylate bulk with DMF, CEP, JDMF, WC offered by Cipla

    Find a price of Celecoxib bulk with DMF, CEP, JDMF, WC offered by Cipla

    Find a price of Etoposide bulk with DMF, CEP, JDMF, WC offered by Cipla

    Find a price of Risedronate Sodium bulk with DMF, CEP, JDMF, WC offered by Cipla

    Find a price of Abacavir Sulfate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Alendronate Sodium bulk with DMF, CEP, WC offered by Cipla

    Find a price of Anastrozole bulk with DMF, CEP, WC offered by Cipla

    Find a price of Bicalutamide bulk with DMF, CEP, WC offered by Cipla

    Find a price of Budesonide bulk with DMF, CEP, WC offered by Cipla

    Find a price of Cetirizine Dihydrochloride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Efinaconazole bulk with DMF, JDMF, WC offered by Cipla

    Find a price of Escitalopram Oxalate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Esomeprazole Magnesium bulk with DMF, CEP, WC offered by Cipla

    Find a price of Exemestane bulk with DMF, CEP, WC offered by Cipla

    Find a price of Felodipine bulk with DMF, CEP, WC offered by Cipla

    Find a price of Finasteride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Fluticasone Propionate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Formoterol Fumarate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Gefitinib bulk with DMF, CEP, WC offered by Cipla

    Find a price of Granisetron Hydrochloride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Imatinib Mesylate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Lamivudine bulk with DMF, CEP, WC offered by Cipla

    Find a price of Leflunomide bulk with DMF, CEP, WC offered by Cipla

    Find a price of Letrozole bulk with DMF, CEP, WC offered by Cipla

    Find a price of Meloxicam bulk with DMF, CEP, WC offered by Cipla

    Find a price of Mometasone Furoate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Omeprazole bulk with DMF, CEP, WC offered by Cipla

    Find a price of Ondansetron Hydrochloride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Oseltamivir Phosphate bulk with DMF, JDMF, WC offered by Cipla

    Find a price of Pantoprazole Sodium bulk with DMF, CEP, WC offered by Cipla

    Find a price of Pirfenidone bulk with DMF, CEP, WC offered by Cipla

    Find a price of Pramipexole Dihydrochloride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Praziquantel bulk with DMF, CEP, WC offered by Cipla

    Find a price of Ramipril bulk with DMF, CEP, WC offered by Cipla

    Find a price of Risperidone bulk with DMF, CEP, WC offered by Cipla

    Find a price of Rivastigmine Tartrate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Salbutamol Sulphate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Solifenacin Succinate bulk with DMF, CEP, WC offered by Cipla

    Find a price of Terbinafine Hydrochloride bulk with DMF, CEP, WC offered by Cipla

    Find a price of Abiraterone Acetate bulk with JDMF, WC offered by Cipla

    Find a price of Beclomethasone Dipropionate bulk with CEP, WC offered by Cipla

    Find a price of Carvedilol bulk with CEP, WC offered by Cipla

    Find a price of Citalopram Hydrobromide bulk with CEP, WC offered by Cipla

    Find a price of Cyproterone Acetate bulk with CEP, WC offered by Cipla

    Find a price of Desloratadine bulk with CEP, WC offered by Cipla

    Find a price of Esomeprazole Magnesium bulk with DMF, CEP offered by Cipla

    Find a price of Fluconazole bulk with CEP, WC offered by Cipla

    Find a price of Lamotrigine bulk with DMF, CEP offered by Cipla

    Find a price of Nevirapine bulk with DMF, WC offered by Cipla

    Find a price of Omeprazole Sodium bulk with CEP, WC offered by Cipla

    Find a price of Rizatriptan Benzoate bulk with CEP, WC offered by Cipla

    Find a price of Salmeterol Xinafoate bulk with CEP, WC offered by Cipla

    Find a price of Tamsulosin bulk with CEP, WC offered by Cipla

    Find a price of Trimetazidine bulk with DMF, CEP offered by Cipla

    Find a price of Venlafaxine Hydrochloride bulk with CEP, WC offered by Cipla

    Find a price of Ambrisentan bulk with DMF, WC offered by Cipla

    Find a price of Anagrelide Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Apremilast bulk with DMF, WC offered by Cipla

    Find a price of Arformoterol Tartrate bulk with DMF, WC offered by Cipla

    Find a price of Atazanavir Sulfate bulk with DMF, WC offered by Cipla

    Find a price of Bosentan Hydrate bulk with DMF, WC offered by Cipla

    Find a price of Capecitabine bulk with WC offered by Cipla

    Find a price of Ciclesonide bulk with CEP, WC offered by Cipla

    Find a price of Cinacalcet Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Danazol bulk with DMF, WC offered by Cipla

    Find a price of Darifenacin Hydrobromide bulk with DMF, WC offered by Cipla

    Find a price of Darunavir Ethanolate bulk with DMF, WC offered by Cipla

    Find a price of Deferasirox bulk with DMF, WC offered by Cipla

    Find a price of Dolutegravir Sodium bulk with DMF, WC offered by Cipla

    Find a price of Eliglustat bulk with DMF, WC offered by Cipla

    Find a price of Empagliflozin bulk with DMF, WC offered by Cipla

    Find a price of Emtricitabine bulk with DMF, WC offered by Cipla

    Find a price of Entecavir bulk with DMF, CEP offered by Cipla

    Find a price of Erlotinib Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Escitalopram Oxalate bulk with DMF, CEP offered by Cipla

    Find a price of Famciclovir bulk with DMF, WC offered by Cipla

    Find a price of Finasteride bulk with WC offered by Cipla

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Cipla

    Find a price of Granisetron bulk with DMF, WC offered by Cipla

    Find a price of Ipratropium Bromide bulk with WC offered by Cipla

    Find a price of Irinotecan Hydrochloride bulk with WC offered by Cipla

    Find a price of Lenalidomide bulk with DMF, WC offered by Cipla

    Find a price of Levocetirizine Dihydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Mebendazole bulk with DMF, WC offered by Cipla

    Find a price of Montelukast Sodium bulk with DMF, WC offered by Cipla

    Find a price of Nintedanib Esylate bulk with DMF, WC offered by Cipla

    Find a price of Olanzapine bulk with WC offered by Cipla

    Find a price of Omeprazole Magnesium bulk with CEP, WC offered by Cipla

    Find a price of Palonosetron bulk with DMF, WC offered by Cipla

    Find a price of Pazopanib Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Ritonavir bulk with DMF, WC offered by Cipla

    Find a price of Rivaroxaban bulk with DMF, CEP offered by Cipla

    Find a price of Telmisartan bulk with DMF, WC offered by Cipla

    Find a price of Tenofovir Disoproxil Fumarate bulk with DMF, WC offered by Cipla

    Find a price of Tiotropium Bromide bulk with CEP, WC offered by Cipla

    Find a price of Topiramate bulk with DMF, WC offered by Cipla

    Find a price of Valacyclovir Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Valganciclovir Hydrochloride bulk with DMF, WC offered by Cipla

    Find a price of Vinblastine Sulfate bulk with WC offered by Cipla

    Find a price of Vincristine Sulfate bulk with WC offered by Cipla

    Find a price of Vortioxetine Hydrobromide bulk with DMF, WC offered by Cipla

    Find a price of Albendazole bulk with WC offered by Cipla

    Find a price of Amlodipine Mesylate bulk with WC offered by Cipla

    Find a price of Artemether bulk with WC offered by Cipla

    Find a price of Artesunate bulk with WC offered by Cipla

    Find a price of Carboplatin bulk with CEP offered by Cipla

    Find a price of Citalopram Hydrobromide bulk with DMF offered by Cipla

    Find a price of Citalopram Hydrobromide bulk with WC offered by Cipla

    Find a price of Daclatasvir bulk with WC offered by Cipla

    Find a price of Darunavir bulk with DMF offered by Cipla

    Find a price of Donepezil bulk with WC offered by Cipla

    Find a price of Efavirenz bulk with DMF offered by Cipla

    Find a price of Flutamide bulk with WC offered by Cipla

    Find a price of Lamivudine bulk with WC offered by Cipla

    Find a price of Lansoprazole bulk with CEP offered by Cipla

    Find a price of Levalbuterol Sulfate bulk with WC offered by Cipla

    Find a price of Lopinavir bulk with DMF offered by Cipla

    Find a price of Losartan Potassium bulk offered by Cipla

    Find a price of Lumefantrine bulk with WC offered by Cipla

    Find a price of Mometasone Furoate bulk with CEP offered by Cipla

    Find a price of Nevirapine bulk with DMF offered by Cipla

    Find a price of Oxaliplatin bulk with CEP offered by Cipla

    Find a price of Paliperidone bulk with WC offered by Cipla

    Find a price of Pregabalin bulk with WC offered by Cipla

    Find a price of Salbutamol Sulphate bulk with CEP offered by Cipla

    Find a price of Saxagliptin Hydrochloride bulk with WC offered by Cipla

    Find a price of Sorafenib bulk with WC offered by Cipla

    Find a price of Temozolomide bulk with WC offered by Cipla

    Find a price of Tenofovir Disoproxil Fumarate bulk with DMF offered by Cipla

    Find a price of Zidovudine bulk with DMF offered by Cipla

    Find a price of Zoledronic Acid bulk with WC offered by Cipla

    Find a price of Abiraterone Acetate bulk with DMF offered by Cipla

    Find a price of Acalabrutinib bulk with DMF offered by Cipla

    Find a price of Albendazole bulk with DMF offered by Cipla

    Find a price of Alfuzosin HCl bulk offered by Cipla

    Find a price of Alosetron Hydrochloride bulk with DMF offered by Cipla

    Find a price of Ambrisentan bulk with WC offered by Cipla

    Find a price of Amlodipine Besylate bulk with CEP offered by Cipla

    Find a price of Apixaban bulk with DMF offered by Cipla

    Find a price of Atazanavir Sulfate bulk with DMF offered by Cipla

    Find a price of Azelastine Hydrochloride bulk offered by Cipla

    Find a price of Beclomethasone Dipropionate bulk with DMF offered by Cipla

    Find a price of Bictegravir Sodium bulk with DMF offered by Cipla

    Find a price of Brexpiprazole bulk with DMF offered by Cipla

    Find a price of Budesonide bulk with CEP offered by Cipla

    Find a price of Cabotegravir bulk with DMF offered by Cipla

    Find a price of Cabotegravir Sodium bulk with DMF offered by Cipla

    Find a price of Cetirizine Dihydrochloride bulk with WC offered by Cipla

    Find a price of Ciprofloxacin Hydrochloride bulk offered by Cipla

    Find a price of Cisplatin bulk with CEP offered by Cipla

    Find a price of Danazol bulk with WC offered by Cipla

    Find a price of Dasatinib bulk with DMF offered by Cipla

    Find a price of Deferiprone bulk with WC offered by Cipla

    Find a price of Difelikefalin bulk with DMF offered by Cipla

    Find a price of Disodium Pamidronate Pentahydrate bulk offered by Cipla

    Find a price of Docetaxel bulk with WC offered by Cipla

    Find a price of Dolutegravir Sodium bulk with DMF offered by Cipla

    Find a price of Donepezil bulk with DMF offered by Cipla

    Find a price of Dutasteride bulk offered by Cipla

    Find a price of Edaravone bulk with DMF offered by Cipla

    Find a price of Entecavir Monohydrate bulk with WC offered by Cipla

    Find a price of Enzalutamide bulk with DMF offered by Cipla

    Find a price of Fexofenadine Hydrochloride bulk offered by Cipla

    Find a price of Fluconazole bulk with DMF offered by Cipla

    Find a price of Fluticasone Furoate bulk with DMF offered by Cipla

    Find a price of Fluticasone Propionate bulk with CEP offered by Cipla

    Find a price of Gemcitabine bulk offered by Cipla

    Find a price of Icatibant Acetate bulk with DMF offered by Cipla

    Find a price of Imatinib Mesylate bulk offered by Cipla

    Find a price of Indacaterol Acetate bulk with DMF offered by Cipla

    Find a price of Isavuconazonium Sulfate bulk with DMF offered by Cipla

    Find a price of Ivabradine Hydrochloride bulk with WC offered by Cipla

    Find a price of Ivacaftor bulk with DMF offered by Cipla

    Find a price of Lenalidomide bulk with DMF offered by Cipla

    Find a price of Levalbuterol Hydrochloride bulk with DMF offered by Cipla

    Find a price of Levalbuterol Tartrate bulk with WC offered by Cipla

    Find a price of Levofloxacin bulk with DMF offered by Cipla

    Find a price of Levofloxacin Hemihydrate bulk with WC offered by Cipla

    Find a price of Levonorgestrel bulk with DMF offered by Cipla

    Find a price of Linagliptin bulk with WC offered by Cipla

    Find a price of Mirabegron bulk with DMF offered by Cipla

    Find a price of Mitoxantrone bulk offered by Cipla

    Find a price of Mometasone Furoate bulk with DMF offered by Cipla

    Find a price of Nateglinide bulk offered by Cipla

    Find a price of Nilotinib bulk with DMF offered by Cipla

    Find a price of Nirmatrelvir bulk with DMF offered by Cipla

    Find a price of Norfloxacin bulk offered by Cipla

    Find a price of Olaparib bulk with DMF offered by Cipla

    Find a price of Olmesartan Medoxomil bulk offered by Cipla

    Find a price of Ondansetron bulk with WC offered by Cipla

    Find a price of Oseltamivir Phosphate bulk with WC offered by Cipla

    Find a price of Paclitaxel bulk with WC offered by Cipla

    Find a price of Pemetrexed Disodium bulk with WC offered by Cipla

    Find a price of Pioglitazone Hydrochloride bulk with DMF offered by Cipla

    Find a price of Pomalidomide bulk with DMF offered by Cipla

    Find a price of Praziquantel bulk with WC offered by Cipla

    Find a price of Relugolix bulk with DMF offered by Cipla

    Find a price of Revefenacin bulk with DMF offered by Cipla

    Find a price of Rilpivirine bulk with DMF offered by Cipla

    Find a price of Rilpivirine Hydrochloride bulk with DMF offered by Cipla

    Find a price of Rizatriptan Benzoate bulk with DMF offered by Cipla

    Find a price of Ruxolitinib Phosphate bulk with DMF offered by Cipla

    Find a price of Salbutamol Sulphate bulk with DMF offered by Cipla

    Find a price of Salmeterol Xinafoate bulk with DMF offered by Cipla

    Find a price of Sertraline Hydrochloride bulk offered by Cipla

    Find a price of Siponimod bulk with DMF offered by Cipla

    Find a price of Sodium Thiosulfate bulk with DMF offered by Cipla

    Find a price of Sorafenib bulk with DMF offered by Cipla

    Find a price of Sumatriptan bulk offered by Cipla

    Find a price of Tafamidis bulk with DMF offered by Cipla

    Find a price of Tegafur bulk with WC offered by Cipla

    Find a price of Tenofovir bulk with WC offered by Cipla

    Find a price of Tenofovir Alafenamide Fumarate bulk with DMF offered by Cipla

    Find a price of Ticagrelor bulk with WC offered by Cipla

    Find a price of Tolterodine Tartrate bulk with DMF offered by Cipla

    Find a price of Umeclidinium Bromide bulk with DMF offered by Cipla

    Find a price of UNII-B7XF2TD73C bulk with WC offered by Cipla

    Find a price of Vilanterol Trifenatate bulk with DMF offered by Cipla

    Find a price of Vinorelbine Tartrate bulk offered by Cipla

    Find a price of Zolpidem Tartrate bulk offered by Cipla

    Find a price of OMEPRAZOLE USP PROCESS-II bulk with DMF offered by Cipla

    Find a price of Aciclovir bulk offered by Cipla

    Find a price of Adefovir Dipivoxil bulk offered by Cipla

    Find a price of Alprazolam bulk offered by Cipla

    Find a price of Androsterone bulk offered by Cipla

    Find a price of Aripiprazole bulk offered by Cipla

    Find a price of Bortezomib bulk offered by Cipla

    Find a price of Celecoxib bulk offered by Cipla

    Find a price of Clonidine bulk offered by Cipla

    Find a price of Clopidogrel bulk offered by Cipla

    Find a price of Darunavir bulk offered by Cipla

    Find a price of Darunavir Ethanolate bulk offered by Cipla

    Find a price of Desloratadine bulk offered by Cipla

    Find a price of Didanosine bulk offered by Cipla

    Find a price of Doxazosin Mesylate bulk offered by Cipla

    Find a price of Drospirenone bulk offered by Cipla

    Find a price of Emtricitabine bulk offered by Cipla

    Find a price of Ibrutinib bulk offered by Cipla

    Find a price of Ibuprofen bulk offered by Cipla

    Find a price of Imiquimod bulk offered by Cipla

    Find a price of Irbesartan bulk offered by Cipla

    Find a price of Lamivudine bulk offered by Cipla

    Find a price of Lorazepam bulk offered by Cipla

    Find a price of Metaproterenol Hemisulfate bulk offered by Cipla

    Find a price of Methocarbamol bulk offered by Cipla

    Find a price of Metoprolol Tartrate bulk offered by Cipla

    Find a price of Moxifloxacin Hydrochloride bulk offered by Cipla

    Find a price of Mycophenolate Mofetil bulk offered by Cipla

    Find a price of Nifedipine bulk offered by Cipla

    Find a price of Ofloxacin bulk offered by Cipla

    Find a price of Olanzapine bulk offered by Cipla

    Find a price of Pantoprazole Sodium bulk offered by Cipla

    Find a price of Pazopanib Hydrochloride bulk offered by Cipla

    Find a price of Perindopril Erbumine bulk offered by Cipla

    Find a price of Podophyllotoxin bulk offered by Cipla

    Find a price of Pomalidomide bulk offered by Cipla

    Find a price of Propranolol Hydrochloride bulk offered by Cipla

    Find a price of Quetiapine Hemifumarate bulk offered by Cipla

    Find a price of Rabeprazole Sodium bulk offered by Cipla

    Find a price of Raloxifene Hydrochloride bulk offered by Cipla

    Find a price of Ranolazine bulk offered by Cipla

    Find a price of Rosiglitazone Maleate bulk offered by Cipla

    Find a price of Salmeterol Xinafoate bulk offered by Cipla

    Find a price of Sibutramine Hydrochloride bulk offered by Cipla

    Find a price of Stavudine bulk offered by Cipla

    Find a price of Tamsulosin bulk offered by Cipla

    Find a price of Terbinafine Hydrochloride bulk offered by Cipla

    Find a price of Terbutaline Sulfate bulk offered by Cipla

    Find a price of Testosterone bulk offered by Cipla

    Find a price of Topotecan Hydrochloride bulk offered by Cipla

    Find a price of Torsemide bulk offered by Cipla

    Find a price of Trioxsalen bulk offered by Cipla

    Find a price of Zaleplon bulk offered by Cipla

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PATALGANGA, INDIA. bulk offered by Cipla

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN KURKUMBH, INDIA. bulk offered by Cipla

    Find a price of PROPANOLOL HCl bulk offered by Cipla

    Find a price of FACILITIES, CONTROLS, AND OPERATING PROC. AT VIKHROLI, INDIA bulk offered by Cipla

    Find a price of FACILITIES, CONTROLS AND OPERATING PROC. AT BOMBAY, INDIA bulk offered by Cipla

    Find a price of FACILITIES, CONTROLS, AND OPERATING PROC. AT BANGALORE, INDIA bulk offered by Cipla

    Find a price of Apalutamide bulk offered by Cipla

    Find a price of Apremilast bulk offered by Cipla

    Find a price of Axitinib bulk offered by Cipla

    Find a price of Baricitinib bulk offered by Cipla

    Find a price of Bictegravir bulk offered by Cipla

    Find a price of CID 69349199 bulk offered by Cipla

    Find a price of CID 9873495 bulk offered by Cipla

    Find a price of Crisaborole bulk offered by Cipla

    Find a price of Dexlansoprazole bulk offered by Cipla

    Find a price of Everolimus bulk offered by Cipla

    Find a price of Favipiravir bulk offered by Cipla

    Find a price of Glatiramer Acetate bulk offered by Cipla

    Find a price of Glycopyrronium Bromide bulk offered by Cipla

    Find a price of Lenvatinib bulk offered by Cipla

    Find a price of Lifitegrast bulk offered by Cipla

    Find a price of Palbociclib bulk offered by Cipla

    Find a price of Pioglitazone bulk offered by Cipla

    Find a price of Ribociclib bulk offered by Cipla

    Find a price of Sacubitril-Valsartan bulk offered by Cipla

    Find a price of Sitagliptin Hydrochloride bulk offered by Cipla

    Find a price of Sitagliptin Phosphate bulk offered by Cipla

    Find a price of Sofosbuvir bulk offered by Cipla

    Find a price of Sorafenib bulk offered by Cipla

    Find a price of Sugammadex Sodium bulk offered by Cipla

    Find a price of Valsartan bulk offered by Cipla

    Find a price of Vildagliptin bulk offered by Cipla

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search